Food and Drug Administration officials have approved another generic variety of the abortion drug mifepristone.
In a letter dated Sept. 30, the FDA said it had approved Evita Solutions’ generic version of Danco Laboratories’ mifepristone.
“We have completed the review of this [new drug application] and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act,” the agency wrote. “We have determined your Mifepristone Tablets, 200 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Mifeprex (mifepristone) tablets, 200 mg, of Danco Laboratories, LLC.”
Evita Solutions announced on its website that the FDA had signed off on its low-cost version of the pill, which is approved for use “up to 70 days from the first day of the last menstrual period.”…